CoChat

Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials

Ridker, Paul M, Lonn, Eva, Paynter, Nina P., Glynn, Robert, Yusuf, Salim · 2017 · Circulation
Cited by 139

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

T he use of statin therapy for secondary prevention is established in all age groups. 1 However, in primary prevention, current cardiovascular guidelines in the United States and Canada describe the role for statin therapy in the elderly as uncertain.To examine this question, we performed a meta-analysis of age-specific outcome data from 2 recent primary prevention statin trials, JUPITER (Justification for Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin) 2 and HOPE-3 (Heart Outcomes Prevention Evaluation). 3We combined new subgroup data from these contemporary trials using a fixed-effect meta-analysis with inverse variance weighting of the log hazard ratios by age group (<65, 65-<70, and ≥70 years) using the meta package in R (R version 3.2.3).The pooled treatment effect within each subgroup was estimated, as was the between-subgroup heterogeneity statistic, Q.The JUPITER trial, published in 2008, evaluated rosuvastatin 20 mg daily among 17 802 men and women free of cardiovascular disease with low-density lipoprotein cholesterol levels <130 mg/dL and high-sensitivity C-reactive protein levels >2 mg/L. 2 For the end point of hard atherosclerotic cardiovascular events (nonfatal myocardial infarction, nonfatal stroke, or cardiovascular death), the JUPITER trial overall reported a 47% reduction in risk (hazard ratio [HR], 0.53; 95% confidence interval [CI], 0.40-0.69;P<0.0001), as well as a 20% reduction in all-cause mortality (HR, 0.80; 95% CI, 0.67-0.97;P=0.02).As shown in the Figure (top), for the 5695 JUPITER participants ≥70 years of age, a comparable 39% reduction in risk was found for this combined cardiovascular end point (HR, 0.61; 95% CI, 0.43-0.86;P=0.004); a nonsignificant 20% reduction in all-cause mortality in this age strata (HR, 0.80; 95% CI, 0.62-1.0;P=0.09) was previously reported. 4These elderly participants, representing 32% of the total JUPITER population, suffered 55% of all the hard atherosclerotic cardiovascular events occurring in the trial.In JUPITER, effects were consistent across age groups, and a formal test for heterogeneity was nonsignificant.Rates of drug withdrawal in the rosuvastatin groups were 14.3%, 17.0%, and 21.6% among those <65, 65 to <70, and ≥70 years of age, respectively.The HOPE-3 trial, published in 2016, evaluated rosuvastatin 10 mg daily among 12 705 men and women free of cardiovascular disease who were at intermediate risk. 3For the identical end point of hard atherosclerotic cardiovascular events, the HOPE-3 trial overall reported a 24% reduction in risk (HR, 0.76; 95% CI, 0.64-0.91;P=0.002) and a 7% nonsignificant reduction in all-cause mortality (HR, 0.93; 95% CI, 0.80-1.08;P=0.32).As also shown in the Figure (top), for the 3086 HOPE-3 participants ≥70 years of age, a comparable nonsignificant 17% reduction in risk was found for the combined cardiovascular end point (HR, 0.83; 95% CI, 0.64-1.07;P=0.16), as well as a comparable nonsignificant 9% reduction in all-cause mortality (HR, 0.91; 95% CI, 0.73-1.13;P=0.38).In HOPE-3, those ≥70 years of age represented 24% of the total trial population yet suffered 43% of all the hard atherosclerotic cardiovascular events.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.117.028271

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 139

Metadata

Authors
Ridker, P. M., Lonn, E., Paynter, N. P., Glynn, R., & Yusuf, S.
Venue
Circulation
Published
2017-05-16
Volume
135
Issue
20
Pages
1979-1981
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W2604860179
Cited by
139
References
5
FWCI
12.63
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.